Humana's shares have experienced a significant drop as the company grapples with a sharp decline in Medicare star ratings for its Advantage plans, leading to concerns over potential revenue losses. With membership in high-rated Medicare plans falling for 2025, analysts warn that Humana may face a $3 billion hit. The stock's performance has plummeted, reaching a 52-week low, with some estimates suggesting a staggering 34% loss for investors over the last year. Industry experts are revising 2026 revenue projections downwards, citing a challenging landscape ahead due to these rating changes.